Technology
Health
Biotechnology

CytomX

$10.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.24 (-2.23%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CytomX and other stocks, options, ETFs, and crypto commission-free!

About

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Read More The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Employees
137
Headquarters
South San Francisco, California
Founded
2010
Market Cap
484.64M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
446.20K
High Today
$10.93
Low Today
$10.21
Open Price
$10.50
Volume
264.82K
52 Week High
$32.55
52 Week Low
$9.38

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2015 IPO
US
North America

News

Yahoo Finance14h

The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM) (NASDAQ: AXSM) Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) (NASDAQ: CPRX) CYCLERION THERA/SH (NASDAQ: CYCNV) (NASDAQ: CYCNV) Veracyte Inc (NASDAQ: VCYT) Down In The Dumps (Biotech stocks hitting 52-week lows on March 25) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (NASDAQ: ADMS) Assembly Biosciences Inc (NASDAQ: ...

33
Seeking AlphaMar 25

CytomX finance chief bids adieu

CytomX Therapeutics (NASDAQ:CTMX) announces that CFO Debanjan Ray will resign on May 15 to accept the CEO job at an unnamed biotech startup.

103
Seeking AlphaFeb 27

CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q4 2018 Results - Earnings Call Transcript

CytomX Therapeutics (NASDAQ:CTMX) Q4 2018 Earnings Conference Call February 27, 2019 5:00 PM ET Company Participants Chris Keenan - VP, IR Sean McCarthy - President, CEO & Chairman Debanjan Ray - CFO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Boris Peaker - Cowen Robert Burns - H.C. Wainwright Mohit Bansal - Citi Jackson Harvey - Nomura Joe Catanzaro - Piper Jaffray Peter Lawson - SunTrust Robinson Operator Good afternoon, and welcome to the CytomX 2018 Full-Ye...

874

Earnings

-$0.74
-$0.33
$0.08
$0.49
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.